Jefferies Financial Group Weighs in on Zealand Pharma A/S’s FY2021 Earnings (NASDAQ:ZEAL)

Zealand Pharma A/S (NASDAQ:ZEAL) – Equities research analysts at Jefferies Financial Group issued their FY2021 EPS estimates for Zealand Pharma A/S in a report issued on Tuesday, January 11th. Jefferies Financial Group analyst L. Codrington expects that the company will earn ($3.67) per share for the year. Jefferies Financial Group has a “Buy” rating on the stock. Jefferies Financial Group also issued estimates for Zealand Pharma A/S’s Q4 2021 earnings at ($1.07) EPS, FY2022 earnings at ($4.89) EPS, FY2023 earnings at ($3.64) EPS, FY2024 earnings at ($2.65) EPS and FY2025 earnings at $0.06 EPS.

Separately, Zacks Investment Research upgraded shares of Zealand Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 17th.

ZEAL stock opened at $21.38 on Thursday. The stock has a market capitalization of $932.90 million, a price-to-earnings ratio of -4.93 and a beta of 1.23. Zealand Pharma A/S has a 1 year low of $19.33 and a 1 year high of $38.21. The stock’s fifty day moving average is $22.45 and its two-hundred day moving average is $27.56.

Zealand Pharma A/S (NASDAQ:ZEAL) last released its quarterly earnings data on Wednesday, November 10th. The company reported ($4.61) EPS for the quarter, topping analysts’ consensus estimates of ($6.31) by $1.70. The firm had revenue of $16.87 million during the quarter, compared to the consensus estimate of $12.21 million. Zealand Pharma A/S had a negative net margin of 371.32% and a negative return on equity of 82.62%. During the same quarter in the previous year, the company posted ($0.90) earnings per share.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. OLD Mission Capital LLC acquired a new position in shares of Zealand Pharma A/S during the second quarter worth approximately $370,000. BlackRock Inc. grew its holdings in shares of Zealand Pharma A/S by 37.3% during the third quarter. BlackRock Inc. now owns 4,028 shares of the company’s stock worth $119,000 after purchasing an additional 1,095 shares during the last quarter. Jacobi Capital Management LLC acquired a new position in shares of Zealand Pharma A/S during the second quarter valued at $27,000. Finally, Morgan Stanley lifted its stake in shares of Zealand Pharma A/S by 7.6% during the third quarter. Morgan Stanley now owns 6,553 shares of the company’s stock valued at $193,000 after acquiring an additional 463 shares during the period. Hedge funds and other institutional investors own 1.78% of the company’s stock.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design and development of peptide based medicines. Its products include Soliqua and Lyxumia. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on October 19, 1998 and is headquartered in Soborg, Denmark.

Recommended Story: What is a put option?

Earnings History and Estimates for Zealand Pharma A/S (NASDAQ:ZEAL)

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.